299660.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 20:31):

Stats
Today's Volume	768.00
Average Volume	60 722.00
Market Cap	53.05B
EPS	KRW-370.82 ( 2023-06-30 )
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW7.85 (0.20%)

Volume Correlation

Long: -0.04 (neutral)

Short: 0.00 (neutral)

Signal:(59.431) Neutral

Cellid, Co., Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cellid, Co., Ltd. Correlation - Currency/Commodity

0.66
( moderate )

0.59
( weak )

0.68
( moderate )

-0.07
( neutral )

0.01
( neutral )

0.24
( neutral )

Cellid, Co., Ltd. Financials

Annual	2023
Revenue:	KRW0
Gross Profit:	KRW-2.66B (0.00 %)
EPS:	KRW-1 078.05

Q4	2023
Revenue:	KRW0
Gross Profit:	KRW-664.54M (0.00 %)
EPS:	KRW-101.87

Q3	2023
Revenue:	KRW0
Gross Profit:	KRW-668.23M (0.00 %)
EPS:	KRW-313.05

Q2	2023
Revenue:	KRW0
Gross Profit:	KRW-667.84M (0.00 %)
EPS:	KRW-337.93

Financial Reports:

No articles found.

Cellid, Co., Ltd.

Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain cancer with PAP/PSMA antigens. The company is also developing BVAC-M for cancers, such as melanoma with GP100/MAGE-A3 antigens; and BVAC-Neo, a customized immunotherapeutic vaccine. Cellid, Inc. was founded in 2006 and is based in Seoul, South Korea.